The Gut-Brain Axis and Its Influence Over Endocannabinoid Tone

I. Introduction

A. Brief Overview of the Gut-Brain Axis

The gut-brain axis represents a bidirectional communication pathway that underpins a broad array of bodily functions, extending beyond digestion to include aspects of immunity, mood, and cognition [1]. Essentially, the gut-brain axis is an intricate network involving the central nervous system, the enteric nervous system, and the gastrointestinal tract [2]. The endocrine, immune, and autonomic nervous systems, mediated by neurotransmitters, hormones, and other signaling molecules, facilitate this dialogue [3]. This axis also incorporates the vast and diverse gut microbiota, microorganisms residing in our gut that can significantly influence our physiology and behavior [4].

B. The Endocannabinoid System: An Overview

On the other hand, the endocannabinoid system, encompassing endogenous cannabinoids (‘endocannabinoids’), their receptors, and related enzymes, functions as a key modulator of homeostasis across the body [5]. Two primary endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), bind to cannabinoid receptors CB1 and CB2, located throughout the brain and body, to regulate a variety of physiological processes [6]. Moreover, enzymes like fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) play pivotal roles in endocannabinoid metabolism, dictating the duration and intensity of endocannabinoid signalling [7].

C. The Importance of Endocannabinoid Tone

The term ‘endocannabinoid tone’ signifies the overall activity of the endocannabinoid system, contingent upon the local concentration of endocannabinoids, the density and state of cannabinoid receptors, and the efficiency of endocannabinoid-metabolizing enzymes [8]. Notably, the endocannabinoid tone can impact a multitude of bodily processes, including mood, appetite, pain sensation, inflammation, and gut motility, and a dysfunctional endocannabinoid tone has been linked to various pathological conditions [9]. As such, understanding and manipulating the endocannabinoid tone may offer new therapeutic avenues for disorders involving both the gut-brain axis and the endocannabinoid system [10].

II. Unraveling the Complexities: The Gut-Brain Axis

A. The Gut Microbiota: A Rich Ecosystem within Us

The gut microbiota, a diverse ecosystem of trillions of bacteria, viruses, fungi, and other microbes residing within our gut, has emerged as a pivotal player in the gut-brain axis [11]. These microbes are not just passive inhabitants, but active participants that contribute to host metabolism, immune function, and even brain development and function [12]. Moreover, they generate a vast array of metabolites, such as short-chain fatty acids, tryptophan metabolites, and bile acids, that can act as signaling molecules influencing the gut-brain axis [13].

B. Biochemical Communication: Neurotransmitters, Hormones, and Metabolites

The gut and brain communicate with each other via several pathways, including hormonal, immunological, and neuronal routes. At the core of this communication are the numerous biochemical mediators, such as neurotransmitters (e.g., serotonin, dopamine), hormones (e.g., ghrelin, leptin), and metabolites produced by gut microbiota [14]. The gut microbiota can influence the synthesis and release of these neurotransmitters, underlining its significant role in gut-brain axis function [15].

C. The Vagus Nerve: A Highway for Information

An essential neural conduit in the gut-brain axis is the vagus nerve, often considered a physical ‘highway’ for information [16]. The vagus nerve, a key component of the parasympathetic nervous system, links the enteric nervous system in the gut and the central nervous system in the brain. It allows rapid, real-time signal transmission between the gut and brain [17]. For example, signals from the gut microbiota can be transmitted to the brain via the vagus nerve, influencing various brain functions, from mood regulation to cognitive processes [18]. Consequently, the vagus nerve holds a critical position in maintaining the delicate balance of the gut-brain axis and modulating the impact of the gut microbiota on brain health [19].”

III. The Endocannabinoid System and Its Pivotal Role

A. Endocannabinoids: The Body’s Natural Cannabinoids

Endocannabinoids, namely anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are internal lipid-based signaling molecules that interact with cannabinoid receptors [20]. These molecules, similar to the body’s natural cannabinoids, are produced as needed from lipid precursors when the body experiences certain events, such as a rise in intracellular calcium [21]. AEA, often called the “bliss molecule,” mainly interacts with the CB1 receptor and participates in various bodily functions, such as mood regulation and pain relief [22]. 2-AG, which is more abundant in the brain than AEA, strongly activates both CB1 and CB2 receptors [23].

B. Cannabinoid Receptors: CB1 and CB2 

Cannabinoid receptors, specifically CB1 and CB2, are protein structures that respond to cannabinoids and are found mainly in the nervous system and immune system. CB1 receptors are abundant in the brain and mediate the mind-altering effects of Δ9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient in cannabis. They are essential for maintaining balance in brain function. CB2 receptors, while less common in the central nervous system, play a significant role in regulating the immune system [25].

C. Endocannabinoid Degradation: FAAH and MAGL

Breaking down endocannabinoids is an equally crucial aspect of the endocannabinoid system. The enzymes fatty acid amide hydrolase (FAAH) for AEA and monoacylglycerol lipase (MAGL) for 2-AG control how long and how intense the endocannabinoid signals are, therefore helping maintain a stable internal endocannabinoid environment [27].

D. The Role of Endocannabinoid Tone in Health and Disease

Endocannabinoid tone refers to the local concentration of endocannabinoids, the amount and state of cannabinoid receptors, and the activity of endocannabinoid breakdown enzymes. This tone is a key factor in many physiological processes [28]. An imbalance in the endocannabinoid system, leading to either too much or too little endocannabinoid tone, has been associated with various conditions, such as neurodegenerative diseases, mental health disorders, epilepsy, pain, inflammation, heart disease, obesity, and metabolic syndrome [29]. As such, adjusting the endocannabinoid tone through medications could offer new ways to treat conditions like anxiety, depression, and chronic pain [30].

IV. The Intersection: Gut-Brain Axis and Endocannabinoid System

A. The Influence of Gut Microbiota on Endocannabinoid Tone

It is now understood that the gut microbiota can impact the endocannabinoid tone, establishing a direct connection between the gut-brain axis and the endocannabinoid system [31]. The microbiota and their metabolic byproducts can change the amount of cannabinoid receptors and endocannabinoids, ultimately affecting the overall endocannabinoid tone [32]. For instance, the gut microbiota can change the amount of FAAH, an enzyme involved in breaking down endocannabinoids, hence controlling the levels of AEA [33]. Disruptions to the gut microbiota, through antibiotics or disease, for example, can impact the endocannabinoid system and its related physiological processes [34]. This connection may open up new avenues for treating a variety of health conditions.

B. The Role of Dietary Factors

Diet can also significantly impact both the gut microbiota and the endocannabinoid system. Certain dietary components, such as omega-3 and omega-6 polyunsaturated fatty acids (PUFAs), are precursors for endocannabinoids and can thus influence endocannabinoid levels [35]. Similarly, dietary fiber, particularly prebiotics that promote the growth of beneficial gut bacteria, can impact the composition of the gut microbiota, leading to changes in the endocannabinoid system [36]

C. Stress, Inflammation, and the Endocannabinoid Response

Stress and inflammation, common factors that can disrupt the gut-brain axis, also significantly influence the endocannabinoid response. Stress can lead to dysbiosis of the gut microbiota, alter endocannabinoid signaling, and influence brain function [37]. Inflammation, on the other hand, can modulate the expression of cannabinoid receptors and the production of endocannabinoids, with subsequent effects on pain, mood, and neuroinflammation [38]. In fact, the anti-inflammatory properties of endocannabinoids and their ability to regulate the immune response have led to growing interest in their potential therapeutic applications in inflammatory disorders [39].

V. Exploring Implications

A. Endocannabinoid Tone and Neurological Disorders

Alterations in the endocannabinoid tone have been associated with several neurological disorders, including multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease [40]. For example, in multiple sclerosis, an inflammatory disorder of the central nervous system, elevated levels of endocannabinoids have been reported, suggesting a compensatory role in controlling inflammation and neurodegeneration [41]. However, further research is required to fully understand the precise roles of the endocannabinoid system in these conditions.

B. The Gut Microbiome, Endocannabinoids, and Mental Health

The complex interplay between the gut microbiome, endocannabinoids, and mental health is now starting to unravel. Both the gut microbiota and the endocannabinoid system are known to influence brain function and behavior, including stress response, mood, and cognition [42]. Emerging evidence suggests that dysregulation of the gut microbiota or the endocannabinoid system may contribute to mental health disorders such as depression and anxiety [43]. Moreover, experimental studies have shown that manipulation of the gut microbiota can alter endocannabinoid signaling in the brain, providing further evidence of the intricate link between the gut-brain-endocannabinoid axis [44].

C. Potential Therapeutic Approaches: Probiotics, Prebiotics, Phytocannabinoids

Given these insights, the modulation of the gut microbiota or the endocannabinoid system, or both, presents potential therapeutic approaches for a range of conditions. Probiotics and prebiotics can beneficially alter the gut microbiota, which may, in turn, influence the endocannabinoid system [45]. Furthermore, phytocannabinoids, such as cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC), have been shown to modulate the endocannabinoid system and exhibit therapeutic potential in a range of conditions, from epilepsy to anxiety disorders [46,47]. However, further research is needed to fully exploit these potential therapeutic strategies and understand their implications for health and disease.

VI. Future Directions and Unanswered Questions

A. Opportunities for Further Research

As our understanding of the intricate relationship between the gut-brain axis and the endocannabinoid system expands, so do the opportunities for further research. There are still many unanswered questions regarding the role of the endocannabinoid system in health and disease. How exactly does the gut microbiota regulate the endocannabinoid system? Which specific microbes and metabolites are involved, and what mechanisms are at play? How can these insights be leveraged to prevent or treat neurological and mental health disorders? These are just a few of the fascinating questions that future research in this field may answer.

B. Potential Challenges and Limitations

However, several challenges and limitations need to be addressed. One major challenge is the complexity and variability of the gut microbiota and the endocannabinoid system. Both are influenced by a multitude of factors, including genetics, diet, lifestyle, and environmental factors, which makes them challenging to study [48]. Additionally, most of our current understanding is based on animal studies, and translating these findings to humans can be problematic due to differences in anatomy, physiology, and microbiota composition [49].

C. Impact on Clinical Practice and Personalized Medicine

Despite these challenges, the potential impact on clinical practice and personalized medicine is immense. The modulation of the gut microbiota or the endocannabinoid system, through interventions such as diet, prebiotics, probiotics, or phytocannabinoids, could provide novel therapeutic approaches for a range of conditions. Furthermore, understanding the individual variability in the gut microbiota and endocannabinoid system could lead to personalized interventions, tailored to an individual’s unique gut microbiota composition and endocannabinoid tone [50]. Future advancements in this field could fundamentally shift our approach to health and disease, moving away from a one-size-fits-all model towards more individualized, holistic, and prevention-focused strategies. As we continue to unravel the complexities of the gut-brain-endocannabinoid axis, the promise of a new era in medicine is on the horizon.

VII. Conclusion

A. Recap of the Gut-Brain Axis and Endocannabinoid System Interplay

The intricate relationship between the gut-brain axis and the endocannabinoid system provides a compelling lens through which to view the complexity of human health and disease [2]. The gut microbiota, through its biochemical messengers, communicates with the brain and plays a pivotal role in regulating behavior, mood, and overall brain function. The endocannabinoid system, with its widespread distribution in the brain and other organs, acts as a key regulator of physiological functions, maintaining internal balance and homeostasis. The interplay between these two systems, mediated by the endocannabinoid tone, represents a burgeoning frontier in biomedical research. Disruptions in this dynamic balance are associated with a range of health disorders, including neurological diseases and mental health conditions [51]. Consequently, modulating the gut microbiota or the endocannabinoid system – or both – could offer novel therapeutic strategies. Moreover, the individual variability in these systems may open the doors for personalized medical interventions [52-53].

B. Emphasizing the Potential of This Research Field

This rapidly evolving field of research is fraught with both challenges and opportunities. The complexity of the gut microbiota and the endocannabinoid system, coupled with the influence of various factors such as diet, lifestyle, and genetics, necessitates nuanced and multifaceted research approaches [50]. However, the potential implications of these insights for improving health and treating disease are immense. As we continue to explore this fascinating confluence of the gut-brain axis and the endocannabinoid system, we stand on the cusp of a promising new era in medicine [8,54]. The study of these complex interactions not only enhances our understanding of health and disease but also provides a compelling example of the beauty and intricacy of life’s processes.

Stefan Broselid, Ph.D.
Editor-In-Chief, Aurea Care Medical Science Journal

References:

1. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-209.
2. Cryan JF, O’Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, Codagnone MG, Cussotto S, Fulling C, Golubeva AV, Guzzetta KE, Jaggar M, Long-Smith CM, Lyte JM, Martin JA, Molinero-Perez A, Moloney G, Morelli E, Morillas E, O’Connor R, Cruz-Pereira JS, Peterson VL, Rea K, Ritz NL, Sherwin E, Spichak S, Teixeira AM, Twomey C, Julia VD, Ventura-Silva AP, Wallace-Fitzsimons SE, Hyland N, Clarke G, Dinan TG. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019;99(4):1877-2013. doi:10.1152/physrev.00018.2018.
3. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci. 2011;12(8):453-466. doi:10.1038/nrn3071.
4. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701-712. doi:10.1038/nrn3346.
5. Di Marzo V, Piscitelli F. The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics. 2015;12(4):692-698. doi:10.1007/s13311-015-0374-6.
6. Mechoulam R, Parker LA. The Endocannabinoid System and the Brain. Annu Rev Psychol. 2013;64:21-47. doi:10.1146/annurev-psych-113011-143739.
7. Pacher P, Bátkai S, Kunos G. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacol Rev. 2006;58(3):389-462. doi:10.1124/pr.58.3.2.
8. Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):623-639. doi:10.1038/nrd.2018.115.
9. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005;(168):299-325. doi:10.1007/3-540-26573-2_10.
10. Hillard CJ. Stress regulates endocannabinoid-CB1 receptor signaling. Semin Immunol. 2014;26(5):380-388. doi:10.1016/j.smim.2014.06.005.
11. Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623-632. doi:10.1038/s41564-018-0337-x.
12. Rinninella E, Raoul P, Cintoni M, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019;7(1):14. doi:10.3390/microorganisms7010014.
13. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461-478. doi:10.1038/s41575-019-0157-3.
14. Cryan JF, O’Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19(2):179-194. doi:10.1016/S1474-4422(19)30356-4.
15. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693(Pt B):128-133. doi:10.1016/j.brainres.2018.03.015.
16. Bonaz B, Bazin T, Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front Neurosci. 2018; 12:49. doi:10.3389/fnins.2018.00049.
17. Breit S, Kupferberg A, Rogler G, Hasler G. Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders. Front Psychiatry. 2018;9:44. doi:10.3389/fpsyt.2018.00044.
18. Martin CR, Osadchiy V, Kalani A, Mayer EA. The Brain-Gut-Microbiome Axis. Cell Mol Gastroenterol Hepatol. 2018;6(2):133-148. doi:10.1016/j.jcmgh.2018.04.003.
19. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-209.
20. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4(11):873-884. doi:10.1038/nrn1247.
21. Mechoulam R, Parker LA. The Endocannabinoid System and the Brain. Annu Rev Psychol. 2013;64:21-47. doi:10.1146/annurev-psych-113011-143739.
22. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. doi:10.1038/sj.bjp.0707442.
23. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3(9):771-784. doi:10.1038/nrd1495.
24. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005;(168):299-325. doi:10.1007/3-540-26573-2_10.
25. Turcotte C, Blanchet MR, Laviolette M, Flamand N. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016;73(23):4449-4470. doi:10.1007/s00018-016-2300-4.
26. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99(16):10819-10824. doi:10.1073/pnas.152334899.
27. Blankman JL, Simon GM, Cravatt BF. A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol. Chem Biol. 2007;14(12):1347-1356. doi:10.1016/j.chembiol.2007.11.006.
28. Alger BE. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacol Rev. 2006;58(3):389-462. doi:10.1124/pr.58.3.2.
29. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20 Suppl 1:10-14. doi:10.1111/j.1365-2826.2008.01671.x.
30. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001;98(16):9371-9376. doi:10.1073/pnas.161191698.
31. Muccioli GG, Naslain D, Bäckhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392. doi:10.1038/msb.2010.46.
32. Cani PD. Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue. Clin Microbiol Infect. 2012;18 Suppl 4:50-53. doi:10.1111/j.1469-0691.2012.03866.x.
33. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13(1):35-37. doi:10.1038/nm1521.
34. Guida F, Turco F, Iannotta M, et al. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain Behav Immun. 2018;67:230-245. doi:10.1016/j.bbi.2017.09.001.
35. Cani PD, Plovier H, Van Hul M, et al. Endocannabinoids–at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol. 2016;12(3):133-143. doi:10.1038/nrendo.2015.211.
36. Di Marzo V, Griinari M, Carta G, et al. Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. Int Dairy J. 2010;20(4):231-235. doi:10.1016/j.idairyj.2009.11.008.
37. Farzi A, Frohlich EE, Holzer P. Gut Microbiota and the Neuroendocrine System. Neurotherapeutics. 2018;15(1):5-22. doi:10.1007/s13311-017-0600-5.
38. Caterina MD, Di Marzo V. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol. 2008;19(2):129-140. doi:10.1097/MOL.0b013e3282f3ed07.
39. Zoppi S, Madrigal JL, Caso JR, et al. Regulatory role of the Cannabinoid-2 receptor in stress-induced neuroinflammation in mice. Br J Pharmacol. 2014;171(11):2814-2826. doi:10.1111/bph.12644.
40. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833. doi:10.3390/ijms19030833.
41. Benito C, Romero JP, Tolon RM, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci. 2007;27(9):2396-2402. doi:10.1523/JNEUROSCI.4814-06.2007.
42. Burokas A, Moloney RD, Dinan TG, Cryan JF. Microbiota regulation of the Mammalian gut-brain axis. Adv Appl Microbiol. 2015;91:1-62. doi:10.1016/bs.aambs.2015.02.001.
43. Sherwin E, Bordenstein SR, Quinn JL, Dinan TG, Cryan JF. Microbiota and the social brain. Science. 2019;366(6465). doi:10.1126/science.aar2016.
44. Guida F, Turco F, Iannotta M, et al. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain Behav Immun. 2018;67:230-245. doi:10.1016/j.bbi.2017.09.001.
45. Burokas A, Arboleya S, Moloney RD, et al. Targeting the Microbiota-Gut-Brain Axis: Prebiotics Have Anxiolytic and Antidepressant-like Effects and Reverse the Impact of Chronic Stress in Mice. Biol Psychiatry. 2017;82(7):472-487. doi:10.1016/j.biopsych.2016.12.031.
46. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4(1):245-259. doi:10.2147/tcrm.s1928.
47. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825-836. doi:10.1007/s13311-015-0387-1.
48. Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. Cell. 2016;167(4):915-932. doi:10.1016/j.cell.2016.10.027.
49. Nguyen TL, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? Dis Model Mech. 2015;8(1):1-16. doi:10.1242/dmm.017400.
50. Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin North Am. 2017;46(1):77-89. doi:10.1016/j.gtc.2016.09.007.
51. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016;1(1):154-165. doi:10.1089/can.2016.0009.
52. Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology. 2018;43(1):155-172. doi:10.1038/npp.2017.130.
53. Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. Nat Med. 2018;24(4):392-400. doi:10.1038/nm.4517.
54. Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716-1725. doi:10.1136/gutjnl-2018-316723